Thirty-seven (95%) of the patients who underwent NDs had HPV-DNA-positive and p16+ cancers, while of the remaining two patients, one had an HPV-DNA-positive and p16− cancer, and the other an HPV-DNA-negative and p16− cancer. Here, CDKN2A is linked to cancer.